Key clinical point: Female corresponding authors are underrepresented among phase 3 oncology trials in the research literature.
Major finding: Among the trials in the analysis, 17.9% had female corresponding authors.
Study details: The findings are based on analysis of 598 oncologic phase 3 RCTs that tested a therapeutic intervention and were published between 2003 and 2018.
Disclosures: The authors did not note any external funding and reported having no disclosures.
Ludmir EB et al. JAMA Oncol. 2019 Aug 8. doi: 10.1001/jamaoncol.2019.2196.